Affimed shares are trading higher after the company announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.
Portfolio Pulse from Benzinga Newsdesk
Affimed shares are trading higher following the release of promising follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort in the ongoing AFM24-102 study for NSCLC.

June 03, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Affimed shares are experiencing an uptick due to the release of positive follow-up and initial clinical efficacy data from their AFM24-102 study in NSCLC.
The positive data from the AFM24-102 study in NSCLC is likely to boost investor confidence in Affimed's pipeline, leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100